title: Immunity to attenuated influenza virus WRL 105 infection induced by heterologous, inactivated influenza A virus vaccines.
abstract: Groups of student volunteers were immunized with one of five different inactivated influenza virus vaccines. The concentration of virus in the various vaccines differed by both the international unitage test and by the concentration of haemagglutinin, as measured by the single radial diffusion test; the results of the two methods of standardization showed no correlation. The serum HI response to immunization was variable; volunteers given A/England/72 showed a 16.6-fold increase in homologous serum antibody titre whilst volunteers given A/Hong Kong/68 vaccine showed a 4.2-fold increase. The variable response of volunteers to immunization could not be explained by the varied concentration of virus in the vaccines, as measured by either test, the titres of serum HI antibody present before immunization, or a combination of these two factors.The ability to infect volunteers with WRL 105 virus 4 weeks after immunization with heterologous, inactivated virus vaccine was directly related to the degree of cross-reactivity between the haemagglutinins of this vaccine virus and WRL 105 virus. Thus, the greatest number of infections by the challenge virus were seen in volunteers given A/Hong Kong/68 vaccine, less were observed in volunteers given A/England/72 vaccine, and least were found in groups given A/Port Chalmers/73 or A/Scotland/74 vaccine. However, compared with the incidence of infection in volunteers given B/Hong Kong/73 vaccine, all the heterologous influenza A vaccine gave some immunity to challenge infection.
mesh_terms: D000914:Antibodies, Viral; D003429:Cross Reactions; D006385:Hemagglutination Inhibition Tests; D006801:Humans; D007114:Immunization; D009980:Influenza A virus / Q000276:immunology*; D007252:Influenza Vaccines; D007251:Influenza, Human / Q000276:immunology*; D009975:Orthomyxoviridae / Q000276:immunology*; D014613:Vaccines, Attenuated
chemical_list: D000914:Antibodies, Viral; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated
references.citation: Lancet. 1975 Aug 2;2(7927):196-9
references.pmid: 51958
references.citation: Bull World Health Organ. 1975;52(2):223-31
references.pmid: 816480
references.citation: J Infect Dis. 1977 Mar;135(3):423-31
references.pmid: 850080
references.citation: Postgrad Med J. 1976 Jun;52(608):345-51
references.pmid: 959115
references.citation: J Hyg (Lond). 1975 Dec;75(3):353-62
references.pmid: 1059705
references.citation: J Hyg (Lond). 1976 Jun;76(3):459-66
references.pmid: 1064672
references.citation: Dev Biol Stand. 1975;28:285-94
references.pmid: 1092575
references.citation: Dev Biol Stand. 1975;28:173-80
references.pmid: 1126567
references.citation: J Biol Stand. 1975;3(1):41-50
references.pmid: 1126961
references.citation: Lancet. 1973 Jul 21;2(7821):116-20
references.pmid: 4124042
references.citation: N Engl J Med. 1973 Dec 13;289(24):1267-71
references.pmid: 4127183
references.citation: Lancet. 1968 Aug 24;2(7565):418-22
references.pmid: 4174153
references.citation: Bull World Health Organ. 1974;51(1):1-11
references.pmid: 4218138
references.citation: JAMA. 1974 Nov 11;230(6):863-6
references.pmid: 4479597
references.citation: Bull World Health Organ. 1973;48(2):199-202
references.pmid: 4541685
references.citation: Br Med J. 1972 Dec 23;4(5842):701-3
references.pmid: 4646846
references.citation: JAMA. 1973 Nov 12;226(7):758-61
references.pmid: 4800628
references.citation: JAMA. 1971 Aug 23;217(8):1067-71
references.pmid: 5109428
references.citation: Mon Bull Minist Health Public Health Lab Serv. 1962 May;21:96-104
references.pmid: 13872351
references.citation: J Immunol. 1962 Mar;88:320-9
references.pmid: 13910995
references.citation: Am J Hyg. 1952 Jan;55(1):12-21
references.pmid: 14885162